Ruolo degli acidi grassi polinsaturi n-3 dopo sindrome coronarica acuta

Pier Luigi Temporelli, Stefano Buda, Stephen J. Greene

Research output: Contribution to journalArticle

Abstract

The role of omega-3 polyunsaturated fatty acids (PUFAs) in the secondary prevention of cardiovascular disease has recently been debated. The GISSI-Prevention trial demonstrated that supplementation with 1 g/day of eicosapentaenoic acid plus docosahexaenoic acid (EPA/DHA) was associated with a reduction in all-cause and cardiovascular mortality in patients with myocardial infarction. However, some subsequent meta-analyses, though not without methodological flaws, did not confirm the beneficial effect on cardiovascular mortality. More evidence has recently become available from the analysis of "real-world" data that point to the effectiveness of PUFA supplementation in reducing cardiovascular events in patients with recent acute coronary syndrome. Meantime, in the determination no. 94 by the Italian Medicines Agency (AIFA), reimbursement of PUFAs containing at least 85% of EPA and DHA has been recognized for 12 months in patients with acute coronary syndrome and ejection fraction >40% and for 18 months in those with ejection fraction ≤40%.

Original languageItalian
Pages (from-to)3S-10S
JournalGiornale Italiano di Cardiologia
Volume17
Issue number7
Publication statusPublished - Jul 1 2016

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ruolo degli acidi grassi polinsaturi n-3 dopo sindrome coronarica acuta. / Temporelli, Pier Luigi; Buda, Stefano; Greene, Stephen J.

In: Giornale Italiano di Cardiologia, Vol. 17, No. 7, 01.07.2016, p. 3S-10S.

Research output: Contribution to journalArticle

@article{ad50f3b69ca343dc9658ae073433f71e,
title = "Ruolo degli acidi grassi polinsaturi n-3 dopo sindrome coronarica acuta",
abstract = "The role of omega-3 polyunsaturated fatty acids (PUFAs) in the secondary prevention of cardiovascular disease has recently been debated. The GISSI-Prevention trial demonstrated that supplementation with 1 g/day of eicosapentaenoic acid plus docosahexaenoic acid (EPA/DHA) was associated with a reduction in all-cause and cardiovascular mortality in patients with myocardial infarction. However, some subsequent meta-analyses, though not without methodological flaws, did not confirm the beneficial effect on cardiovascular mortality. More evidence has recently become available from the analysis of {"}real-world{"} data that point to the effectiveness of PUFA supplementation in reducing cardiovascular events in patients with recent acute coronary syndrome. Meantime, in the determination no. 94 by the Italian Medicines Agency (AIFA), reimbursement of PUFAs containing at least 85{\%} of EPA and DHA has been recognized for 12 months in patients with acute coronary syndrome and ejection fraction >40{\%} and for 18 months in those with ejection fraction ≤40{\%}.",
keywords = "Acute coronary syndrome, Polyunsaturated fatty acids",
author = "Temporelli, {Pier Luigi} and Stefano Buda and Greene, {Stephen J.}",
year = "2016",
month = "7",
day = "1",
language = "Italian",
volume = "17",
pages = "3S--10S",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "7",

}

TY - JOUR

T1 - Ruolo degli acidi grassi polinsaturi n-3 dopo sindrome coronarica acuta

AU - Temporelli, Pier Luigi

AU - Buda, Stefano

AU - Greene, Stephen J.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The role of omega-3 polyunsaturated fatty acids (PUFAs) in the secondary prevention of cardiovascular disease has recently been debated. The GISSI-Prevention trial demonstrated that supplementation with 1 g/day of eicosapentaenoic acid plus docosahexaenoic acid (EPA/DHA) was associated with a reduction in all-cause and cardiovascular mortality in patients with myocardial infarction. However, some subsequent meta-analyses, though not without methodological flaws, did not confirm the beneficial effect on cardiovascular mortality. More evidence has recently become available from the analysis of "real-world" data that point to the effectiveness of PUFA supplementation in reducing cardiovascular events in patients with recent acute coronary syndrome. Meantime, in the determination no. 94 by the Italian Medicines Agency (AIFA), reimbursement of PUFAs containing at least 85% of EPA and DHA has been recognized for 12 months in patients with acute coronary syndrome and ejection fraction >40% and for 18 months in those with ejection fraction ≤40%.

AB - The role of omega-3 polyunsaturated fatty acids (PUFAs) in the secondary prevention of cardiovascular disease has recently been debated. The GISSI-Prevention trial demonstrated that supplementation with 1 g/day of eicosapentaenoic acid plus docosahexaenoic acid (EPA/DHA) was associated with a reduction in all-cause and cardiovascular mortality in patients with myocardial infarction. However, some subsequent meta-analyses, though not without methodological flaws, did not confirm the beneficial effect on cardiovascular mortality. More evidence has recently become available from the analysis of "real-world" data that point to the effectiveness of PUFA supplementation in reducing cardiovascular events in patients with recent acute coronary syndrome. Meantime, in the determination no. 94 by the Italian Medicines Agency (AIFA), reimbursement of PUFAs containing at least 85% of EPA and DHA has been recognized for 12 months in patients with acute coronary syndrome and ejection fraction >40% and for 18 months in those with ejection fraction ≤40%.

KW - Acute coronary syndrome

KW - Polyunsaturated fatty acids

UR - http://www.scopus.com/inward/record.url?scp=84984685570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984685570&partnerID=8YFLogxK

M3 - Articolo

VL - 17

SP - 3S-10S

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 7

ER -